<DOC>
	<DOCNO>NCT01854996</DOCNO>
	<brief_summary>This study aim test plasma exposure PF-05089771 formulation use phase II trial ( capsule ) .</brief_summary>
	<brief_title>Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12lead ECG clinical laboratory test ) . Females must nonchildbearing potential . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . An informed consent document sign date subject legally acceptable representative , indicate subject inform pertinent aspects trial . Subjects willing able comply schedule visit , treatment plan , laboratory test , study procedure Evidence history clinically significant hematological , renal ( i.e recurrent uric nephrolithiasis ) , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Any condition possibly affect drug absorption ( eg , gastrectomy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>